Monte Rosa Therapeutics (NASDAQ:GLUE) Insider Filip Janku Sells 5,407 Shares of Stock

Monte Rosa Therapeutics, Inc. (NASDAQ:GLUE) insider Filip Janku sold 5,407 shares of Monte Rosa Therapeutics stock in a transaction that occurred on Tuesday, June 30th. The stock was sold at an average price of $24.50, for a total transaction of $132,471.50. Following the completion of the sale, the insider directly owned 60,612 shares of the company’s stock, valued at approximately $1,484,994. This trade represents a 8.19% decrease in their position. The transaction was disclosed in a document filed with the SEC, which can be accessed through this hyperlink.

Filip Janku also recently made the following trade(s):

• On Monday, June 29th, Filip Janku sold 6,000 shares of Monte Rosa Therapeutics stock. The shares were sold at an average price of $22.95, for a total value of $137,700.00.
• On Tuesday, June 23rd, Filip Janku sold 11,845 shares of Monte Rosa Therapeutics stock. The stock was sold at an average price of $20.22, for a total value of $239,505.90.
• On Wednesday, June 24th, Filip Janku sold 30,000 shares of Monte Rosa Therapeutics stock. The stock was sold at an average price of $21.42, for a total value of $642,600.00.

Monte Rosa Therapeutics Stock Performance

Monte Rosa Therapeutics stock opened at $24.02 on Thursday. Monte Rosa Therapeutics, Inc. has a one year low of $4.12 and a one year high of $25.77. The stock has a fifty day moving average of $19.24 and a 200 day moving average of $18.79. The stock has a market cap of $2.03 billion, a PE ratio of -16.23 and a beta of 1.55.

Monte Rosa Therapeutics (NASDAQ:GLUE) last issued its quarterly earnings data on Thursday, May 7th. The company reported ($0.45) earnings per share for the quarter, missing the consensus estimate of ($0.39) by ($0.06). The business had revenue of $4.21 million during the quarter, compared to the consensus estimate of $10.95 million. Monte Rosa Therapeutics had a negative return on equity of 40.99% and a negative net margin of 302.69%. As a group, sell-side analysts predict that Monte Rosa Therapeutics, Inc. will post -1.23 EPS for the current fiscal year.

Institutional Trading of Monte Rosa Therapeutics

Hedge funds and other institutional investors have recently modified their holdings of the company. GAMMA Investing LLC bought a new stake in shares of Monte Rosa Therapeutics during the 4th quarter valued at $30,000. Nisa Investment Advisors LLC increased its stake in Monte Rosa Therapeutics by 16.7% in the 4th quarter. Nisa Investment Advisors LLC now owns 3,151 shares of the company’s stock worth $49,000 after buying an additional 451 shares in the last quarter. Mirae Asset Global Investments Co. Ltd. raised its holdings in Monte Rosa Therapeutics by 32.5% during the fourth quarter. Mirae Asset Global Investments Co. Ltd. now owns 3,164 shares of the company’s stock valued at $50,000 after acquiring an additional 776 shares during the period. Seven Fleet Capital Management LP bought a new stake in Monte Rosa Therapeutics during the fourth quarter valued at about $63,000. Finally, Russell Investments Group Ltd. purchased a new position in shares of Monte Rosa Therapeutics in the third quarter valued at about $32,000. 79.96% of the stock is owned by hedge funds and other institutional investors.

Analysts Set New Price Targets

Several research analysts have recently weighed in on the stock. Wells Fargo & Company dropped their price target on shares of Monte Rosa Therapeutics from $30.00 to $29.00 and set an “overweight” rating on the stock in a research note on Wednesday, March 18th. Wall Street Zen cut Monte Rosa Therapeutics from a “hold” rating to a “sell” rating in a report on Saturday, March 21st. JPMorgan Chase & Co. lifted their target price on Monte Rosa Therapeutics from $30.00 to $31.00 and gave the company an “overweight” rating in a research report on Monday, May 11th. Weiss Ratings raised Monte Rosa Therapeutics from a “sell (d-)” rating to a “sell (d)” rating in a report on Monday, May 11th. Finally, Guggenheim upped their price target on Monte Rosa Therapeutics from $30.00 to $35.00 and gave the stock a “buy” rating in a research report on Tuesday. Seven research analysts have rated the stock with a Buy rating, one has given a Hold rating and one has issued a Sell rating to the stock. According to data from MarketBeat, the stock has an average rating of “Moderate Buy” and a consensus price target of $33.33.

Monte Rosa Therapeutics Company Profile

Monte Rosa Therapeutics is a biotechnology company focused on accelerating drug discovery through the integration of single-cell genomics and artificial intelligence. Founded in 2020 and headquartered in Cambridge, Massachusetts, the company has built a proprietary platform designed to identify novel therapeutic targets and optimize lead candidates for areas of high unmet medical need. By combining cutting-edge computational methods with comprehensive cellular profiling, Monte Rosa aims to streamline the preclinical development process and uncover insights into disease biology that might otherwise remain hidden.

The company’s main business activities center on using its AI-driven discovery engine to pursue programs in immuno-oncology and neuroscience.